share_log

Enzo Therapeutics Awarded U.S. Patent 10,945,971 'Sphingosine kinase type 1 inhibitors and uses thereof'

Enzo Therapeutics Awarded U.S. Patent 10,945,971 'Sphingosine kinase type 1 inhibitors and uses thereof'

恩佐治疗公司获得美国专利10,945,971“鞘氨醇激酶1型抑制剂及其用途”
Benzinga Real-time News ·  2021/03/16 19:16

Provided are inhibitors of sphingosine kinase Type I that are useful in a number of applications, indications and diseases, as well as for monitoring pharmacokinetics and patient management. These compounds are applicable to treating ischemic diseases such as myocardial infarction and stroke.

本发明提供了在许多应用、适应症和疾病中有用的鞘氨醇激酶I型抑制剂，以及用于监测药代动力学和患者管理的抑制剂。这些化合物适用于治疗心肌梗死和中风等缺血性疾病。

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发